Latest Market News

Cedar Woods Properties has updated its dividend announcement for the six months ending June 2025, confirming a fully franked 19 cents per share payout and revealing key details on its Dividend Reinvestment and Bonus Security Plans.

Cedar Woods Properties has activated its Dividend Reinvestment and Bonus Share Plans for the final 2025 dividend, offering shares at a 2.5% discount and backed by full underwriting from major brokers.

Canterbury Resources is on the cusp of completing a pivotal scoping study for its Briggs Copper Project, while deep drilling advances to unlock higher-grade mineralisation. The company also moves forward with new exploration initiatives and a share purchase plan to bolster funding.

AustChina Holdings has received a non-binding proposal from Bluestone Energy to invest $1.5 million via a large share placement, potentially fueling new acquisitions and exploration efforts.

Clime Investment Management has completed a $2.3 million placement and announced a bonus option issue, positioning itself for growth as the Australian wealth management sector consolidates.

Cryosite Limited reports a strong start to FY26 with a 22% revenue increase and a strategic warehouse acquisition that doubles capacity, positioning the company for sustained growth in clinical trial logistics.

Yandal Resources has confirmed a significant new gold discovery at its Arrakis Prospect with broad mineralisation over a 2.2km strike. Diamond drilling is set to commence imminently to further define the system.

Australian Mines Limited has secured key approvals to begin a ~1,000m drilling program at its high-grade Flemington scandium project, positioning itself strategically amid tightening Chinese rare earth export controls.

Omnia Metals Group has addressed ASX concerns over unusual trading activity, confirming receipt and forthcoming disclosure of assay results from its Salt Creek drilling program.

Equity Trustees faces an expanded Federal Court claim from ASIC seeking compensation for superannuation members after a $73 million revaluation hit the Shield Master Fund. The trustee disputes liability and supports liquidation efforts to recover member funds.

INOVIQ Limited has launched an A$11.5 million capital raise to fast-track clinical validation and commercialization of its ovarian cancer screening test and advance its CAR-exosome therapeutic program targeting solid tumors.

INOVIQ Limited has raised $11.5 million through a $9.5 million placement and a $2 million share purchase plan to accelerate the development and commercialisation of its EXO-OC ovarian cancer test and exosome therapeutic program.